Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 18,750 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 18,750 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $56.51, for a total transaction of $1,059,562.50. Following the completion of the transaction, the insider now owns 170,237 shares of the company's stock, valued at approximately $9,620,092.87. This represents a 9.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Timothy Rolph also recently made the following trade(s):

• On Monday, January 27th, Timothy Rolph sold 31,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.77, for a total value of $1,742,812.50.
• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total value of $148,924.38.

Akero Therapeutics Stock Performance

Shares of NASDAQ AKRO traded down $0.94 during mid-day trading on Tuesday, reaching $50.21. 992,694 shares of the company were exchanged, compared to its average volume of 1,861,046. The stock has a market capitalization of $3.50 billion, a P/E ratio of -13.38 and a beta of -0.11. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The company's 50-day simple moving average is $33.42 and its 200-day simple moving average is $30.24.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock worth $71,000 after purchasing an additional 446 shares during the period. Eastern Bank acquired a new stake in shares of Akero Therapeutics during the third quarter valued at about $100,000. Summit Financial Wealth Advisors LLC acquired a new position in Akero Therapeutics in the 3rd quarter valued at approximately $205,000. Victory Capital Management Inc. bought a new position in Akero Therapeutics during the 3rd quarter worth $211,000. Finally, AlphaQuest LLC lifted its stake in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after acquiring an additional 8,147 shares during the period.

Wall Street Analyst Weigh In

Several research firms have recently commented on AKRO. Morgan Stanley increased their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Canaccord Genuity Group boosted their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. UBS Group increased their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Finally, HC Wainwright boosted their price objective on shares of Akero Therapeutics from $50.00 to $72.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $75.86.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.